Featured Article
The research in animal models suggests that these new therapies could not only treat Alzheimer’s, but also other neurodegenerative diseases characterized by protein aggregation, such as motor neurone disease, Huntington’s disease, and Parkinson’s disease.
Precision Oncology Today
Magazine
Minimal Disease, Maximum Benefit
As both flow cytometry technology and genomic sequencing have taken technological leaps forward, the sensitivity and specificity of testing has increased to include MRD for solid tumors. Leveraging advances in next-generation sequencing, MRD test developers can look for thousands of disease markers and even detect one cancerous cell among a million healthy cells. This level of sensitivity provides evidence of disease recurrence months before traditional follow-up screening methods.
Immunogenomics is on the Way Up
Combining immune-system science, omics, and various computational algorithms might produce success where advanced cancer treatments have failed.
Trending on Inside Precision Medicine
Study Identifies Key Factors for Long-Term Weight Loss with GLP-1 Medications
A recent Cleveland Clinic study has shed light on the critical factors influencing long-term weight loss in patients with obesity prescribed GLP-1 receptor agonist (RA) medications like semaglutide (Wegovy, Ozempic) and liraglutide (Saxenda, Victoza).
AI Effectively Allocates Resources in Pandemic
Research suggests that machine learning could have helped reduce hospitalizations by more than a quarter during the COVID-19 pandemic by determining how to best allocate limited resources, in the form of personalized public health decision making.
New Therapy Shows Promise in Targeting Tau Tangles in Alzheimer’s Disease
The research in animal models suggests that these new therapies could not only treat Alzheimer’s, but also other neurodegenerative diseases characterized by protein aggregation, such as motor neurone disease, Huntington’s disease, and Parkinson’s disease.
